Zentalis Pharmaceuticals, INC 8-K filings

Zentalis Pharmaceuticals reports Q2 2026 results, with its lead drug azenosertib showing continued progress in ovarian cancer trials, aiming for accelerated approval.

Zentalis Pharmaceuticals, Inc. reported the results of its 2026 Annual Meeting of Stockholders, confirming the election of two Class III directors and the ratification of its independent auditor.

Zentalis Pharmaceuticals, Inc. announced the appointment of Shannon Campbell as a Class I director, expanding the Board of Directors from six to seven members.

Zentalis Pharmaceuticals announced encouraging clinical activity for azenosertib combined with paclitaxel in platinum-resistant ovarian cancer patients.

Zentalis Pharmaceuticals has dosed the first patient in its Phase 3 ASPENOVA clinical trial evaluating azenosertib for platinum-resistant ovarian cancer, a step towards potential full approval.

Zentalis Pharmaceuticals presented new preclinical data for azenosertib in triple-negative breast cancer and real-world evidence in ovarian cancer at the 2026 AACR Annual Meeting.

Zentalis Pharmaceuticals announced the selection of 400mg QD 5:2 as the optimal monotherapy dose for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer, advancing pivotal trials.

Zentalis Pharmaceuticals announced its full year 2025 financial results and provided key updates on its late-stage ovarian cancer drug, azenosertib, including trial progress and a cash runway into late 2027.

Zentalis Pharmaceuticals provides a corporate update, highlighting significant progress in its azenosertib development program for platinum-resistant ovarian cancer and an extended cash runway into late 2027.

Zentalis Pharmaceuticals repurchased 7.5 million shares from Matrix Capital at a discount following a director's resignation, with no expected impact on its cash runway.

Zentalis Pharmaceuticals announced Q3 2025 financial results and positive operational progress for its lead ovarian cancer drug, azenosertib, extending its cash runway into late 2027.

Zentalis Pharmaceuticals announced the appointment of James B. Bucher as its new Chief Legal Officer and Corporate Secretary, effective September 18, 2025, following Andrea Paul's resignation.

Zentalis Pharmaceuticals announced its second quarter 2025 financial results, highlighting significant progress in its DENALI Phase 2 clinical trial for azenosertib and an extended cash runway into late 2027.

Zentalis Pharmaceuticals, Inc. announced the successful election of three Class II directors, the ratification of its independent auditor, and the advisory approval of executive compensation at its 2025 Annual Meeting of Stockholders.

Zentalis Pharmaceuticals, Inc. announced positive Phase 1 dose escalation results for its WEE1 inhibitor azenosertib in combination with encorafenib and cetuximab for previously treated BRAFV600E mutant metastatic colorectal cancer patients, presented at the 2025 ASCO Annual Meeting.

Zentalis Pharmaceuticals announces its participation in three investor conferences in May and June 2025.

Zentalis Pharmaceuticals announced its Q1 2025 financial results and highlighted the first patient dosed in the DENALI Part 2a clinical trial of azenosertib, with topline data expected by year-end 2026.

Zentalis Pharmaceuticals showcases preclinical data at the AACR 2025 Annual Meeting, highlighting the potential of azenosertib, a WEE1 inhibitor, in various cancer settings, including RB1-deficient tumors and BRAF-mutated colorectal cancer.

Zentalis Pharmaceuticals announced its full year 2024 financial results, highlighting positive clinical data for azenosertib and a cash runway into late 2027.

Zentalis Pharmaceuticals presents updated clinical data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer, highlighting azenosertib's potential in treating platinum-resistant ovarian cancer.

Zentalis Pharmaceuticals will prioritize the development of azenosertib for patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC) following encouraging clinical trial results.

Zentalis Pharmaceuticals is restructuring its operations, including a 40% workforce reduction, to prioritize the development of its lead drug candidate, azenosertib, and extend its cash runway.

Zentalis Pharmaceuticals has appointed Scott Myers to its Compensation Committee, effective immediately, and has disclosed the additional compensation he will receive for this role.

Zentalis Pharmaceuticals has announced a significant leadership overhaul, including a new CEO, Chief Medical Officer, and Board Chairperson, to focus on advancing its lead drug candidate, azenosertib, through registrational clinical studies.

The FDA has lifted the partial clinical hold on Zentalis Pharmaceuticals' azenosertib studies, allowing the company to resume enrollment in all ongoing trials.

Zentalis Pharmaceuticals announced its second quarter 2024 financial results, highlighted by a partial clinical hold on azenosertib and a pipeline adjustment, while maintaining a cash runway into mid-2026.

Zentalis Pharmaceuticals held its 2024 Annual Meeting of Stockholders, where key proposals including the election of directors and ratification of the company's auditor were approved.

Zentalis Pharmaceuticals is advancing its WEE1 inhibitor, azenosertib, with multiple clinical trials and a focus on gynecologic cancers and beyond, aiming for a potential first NDA in 2026.

Zentalis Pharmaceuticals has increased its board size to seven members and appointed Dr. Luke Walker as a Class II director, effective May 24, 2024.

Zentalis Pharmaceuticals announced its first quarter 2024 financial results and provided updates on its clinical development programs, highlighting progress with its lead candidate, azenosertib.